Stereotaxis (STXS) M&A announcement summary

Deal rationale and strategic fit

• Acquisition combines complementary robotic technologies, accelerating leadership in robotic platforms for endovascular procedures, including interventional cardiology, neurointerventions, and electrophysiology.

• Robocath's mechanical grasper technology complements magnetic navigation, enabling fully robotic and potentially remote procedures.

• The deal leverages Robocath's clinical experience and IP portfolio, creating a strong competitive barrier.

• Expands reach and impact in minimally invasive therapies, supporting strategic growth opportunities and entry into large, high-growth markets.

• The combined technologies target complex procedures and broader automation in cath labs.

Financial terms and conditions

• Upfront payment of $20 million, with up to $25 million in contingent payments tied to FDA clearance and commercial milestones.

• All payments can be made in cash or stock, with the upfront portion in stock at a minimum price of $2 per share.

• Robocath expected to contribute approximately $2 million in annual revenue in the first year post-acquisition.

• Incremental annual operating expense of about $5 million from Robocath.

• Acquisition expected to close mid-2026, subject to customary conditions.

Synergies and expected cost savings

• Integration of proprietary hardware and software will enhance Robocath's system with advanced features like automation and OR integration.

• Commercial and operational synergies anticipated to support break-even by year three.

• Commercial teams will sell both technologies independently and in combination, maximizing market reach.